WoodburnJ.R.: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther, 82: 241–250, 1999.
2.
SalomonD.S., BrandtR., CiardielloF., NormannoN.: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Haematol, 19: 183–232, 1995.
3.
MendelsohnJ.: Blockade of receptors for growth factors: an anticancer therapy. Clin Cancer Res, 6: 747–753, 2000.
4.
CiardielloF., TortoraG.: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 7: 2958–2970, 2001.
5.
CiardielloF., CaputoR., BiancoR., DamianoV., PomaticoG., De PlacidoS., BiancoA.R., TortoraG.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res, 6: 2053–2063, 2000.
6.
SirotnakF.M., ZakowskyM.F., MillerV.A., ScherHI., KrisM.G.: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res, 6: 4885–4892, 2000.
7.
CiardielloF., CaputoR., BiancoR., DamianoV., FontaniniG., CuccatoS., De PlacidoS., BiancoA.R., TortoraG.: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res, 7: 1459–1465, 2001.
8.
BaselgaJ., HerbstR., LoRussoP., RischinD., RansonM., PlummerR., RaymondE., MaddoxA., KayeS, KiebackD., HarrisA., OchsJ.: Continuous administration of ZD1839 (Tressa’), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc ASCO, 19: 686a, 2000.
9.
GossG., HirteH., LorimerI., MillerW., StewartD., BatistG., MatthewsS., SeymourL.: Final results of the dose-escalation phase of a phase I, dose-escalation, pharmacokinetics (PK) and pharmacodynamic study of ZD1839: NCIC CTG IND.122. Proc ASCO, 21: 2368a, 2001.
10.
MillerV.A., JohnsonD., HeelanR.T., PizzoB.A., PerezW.J., BassA., KrisM.G., OchsJ., AverbuchS.: A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C and paclitaxel (P) in previously untreated advanced non-small lung cancer (NSLC). Proc ASCOLI:1301a, 2001.
11.
AlbanellJ., RojoF., AverbuchS., FeyereislovaA., MascaroJ.M., HerbstR., LoRussoP., RischinD., SauledaS., GeeJ., NicholsonR.I., BaselgaJ.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular conbsequences of receptor inhibition. J Clin Oncol, 20: 110–124, 2002.
